CR20220122A - Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Info

Publication number
CR20220122A
CR20220122A CR20220122A CR20220122A CR20220122A CR 20220122 A CR20220122 A CR 20220122A CR 20220122 A CR20220122 A CR 20220122A CR 20220122 A CR20220122 A CR 20220122A CR 20220122 A CR20220122 A CR 20220122A
Authority
CR
Costa Rica
Prior art keywords
nrp1a
antibodies
ocular diseases
treating eye
eye
Prior art date
Application number
CR20220122A
Other languages
English (en)
Inventor
Pankaj Gupta
Juergen Prestle
Nina Zippel
Yining Huang
Sarah Low
Leo Thomas
Fei Han
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20220122A publication Critical patent/CR20220122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre el domino A de Neuropilina-1 (Nrp1A). Más específicamente, se divulgan anticuerpos anti-Nrp1A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
CR20220122A 2019-09-24 2020-09-24 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares CR20220122A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24
EP20150942 2020-01-09
PCT/EP2020/076685 WO2021058636A1 (en) 2019-09-24 2020-09-24 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
CR20220122A true CR20220122A (es) 2022-05-05

Family

ID=72752879

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220122A CR20220122A (es) 2019-09-24 2020-09-24 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Country Status (20)

Country Link
US (2) US11661458B2 (es)
EP (1) EP4034161A1 (es)
JP (1) JP7691976B2 (es)
KR (1) KR20220069076A (es)
CN (1) CN114423788B (es)
AU (1) AU2020355599A1 (es)
BR (1) BR112022005024A2 (es)
CA (1) CA3154654A1 (es)
CO (1) CO2022003324A2 (es)
CR (1) CR20220122A (es)
DO (1) DOP2022000059A (es)
IL (1) IL291522A (es)
JO (1) JOP20220074A1 (es)
MX (1) MX2022003544A (es)
MY (1) MY208919A (es)
PE (1) PE20221315A1 (es)
PH (1) PH12022550619A1 (es)
SA (1) SA522432069B1 (es)
TW (1) TWI859339B (es)
WO (1) WO2021058636A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (es)
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1858542A4 (en) 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AU2011253904B2 (en) 2005-11-08 2014-02-13 Genentech, Inc. Neuropilin antagonists
EP1947114A1 (en) 2007-01-19 2008-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated netrin 4, fragments thereof and uses thereof as drugs
KR101523788B1 (ko) 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
JP6437462B2 (ja) * 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
MX2016009331A (es) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
RS61703B1 (sr) * 2014-09-05 2021-05-31 Rsem Limited Partnership Kompozicije i postupci za lečenje i prevenciju zapaljenja
WO2016089126A1 (ko) 2014-12-03 2016-06-09 사회복지법인 삼성생명공익재단 뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途

Also Published As

Publication number Publication date
MX2022003544A (es) 2022-04-11
JOP20220074A1 (ar) 2023-01-30
BR112022005024A2 (pt) 2022-06-21
DOP2022000059A (es) 2022-05-31
US20210087282A1 (en) 2021-03-25
CA3154654A1 (en) 2021-04-01
CN114423788A (zh) 2022-04-29
US20230416378A1 (en) 2023-12-28
TWI859339B (zh) 2024-10-21
PH12022550619A1 (en) 2022-11-21
SA522432069B1 (ar) 2024-10-29
EP4034161A1 (en) 2022-08-03
JP2022549005A (ja) 2022-11-22
TW202126685A (zh) 2021-07-16
AU2020355599A1 (en) 2022-04-07
PE20221315A1 (es) 2022-09-07
MY208919A (en) 2025-06-11
IL291522A (en) 2022-05-01
WO2021058636A1 (en) 2021-04-01
KR20220069076A (ko) 2022-05-26
US11661458B2 (en) 2023-05-30
CN114423788B (zh) 2025-04-01
US12540187B2 (en) 2026-02-03
CO2022003324A2 (es) 2022-04-19
JP7691976B2 (ja) 2025-06-12

Similar Documents

Publication Publication Date Title
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
NI202100018A (es) Moduladores de la expresión de pnpla3
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
NI202000085A (es) Moduladores de la expresión de apol1
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2019007788A (es) Composiciones y metodos para tratar condiciones de la piel mediante el uso de luz y clorhidrato de glucosamina.
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
CR20220122A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2020003554A (es) Moduladores de la expresion de enac.
AR121317A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2023000955A1 (es) Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombótica de la retina
AR117079A1 (es) Moduladores de la expresión de foxp3
EA202091111A1 (ru) Модуляторы интегрированного стресса